AR124973A1 - Nuevos derivados de pirimidina-2-il sulfonamida - Google Patents

Nuevos derivados de pirimidina-2-il sulfonamida

Info

Publication number
AR124973A1
AR124973A1 ARP220100414A ARP220100414A AR124973A1 AR 124973 A1 AR124973 A1 AR 124973A1 AR P220100414 A ARP220100414 A AR P220100414A AR P220100414 A ARP220100414 A AR P220100414A AR 124973 A1 AR124973 A1 AR 124973A1
Authority
AR
Argentina
Prior art keywords
alkyl
haloalkoxy
alkoxy
heterocycloalkyl
haloalkyl
Prior art date
Application number
ARP220100414A
Other languages
English (en)
Inventor
Guido Galley
Wolfgang Guba
Dmitry Mazunin
Emmanuel Pinard
Antonio Ricci
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR124973A1 publication Critical patent/AR124973A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Reivindicación 1: Compuestos de fórmula (1) en los que R¹ es H, halo, alquilo, alcoxi, alcoxialquilo, alcoxialcoxi, cianoalquilo, haloalquilo, haloalcoxi, tioalquilo, cicloalquilo, cicloalquilalquilo, cicloalcoxi o heterocicloalquilo; R² es ciano, halo, alquilo, alquenilo, alquinilo, alcoxi, alquenilalquilo, alquinilalcoxi, alcoxialquilo, alcoxialcoxi, haloalquilo, haloalcoxi, haloalcoxialquilo, (haloalcoxi)alcoxi, cianoalquilo, cianoalcoxi, tioalquilo, halotioalquilo, halohidroxialcoxi, alquilsulfonilalquilo, cicloalquilo, cicloalquilalquilo, cicloalquilalcoxi, cicloalcoxi, heterocicloalquilo, heterocicloalquilalquilo, heterocicloalquilalquinilo o heterocicloalquilalcoxi; R³ es H, halo, alquilo, alcoxi, haloalcoxi o tiolalquilo; X¹ es CR⁵ o N; X² es NH, -N-R⁶, S, -S(O)- o -S(O₂)-; R⁴ es H, halo, alquilo, hidroxialquilo, tioalquilo, cianoalquilo, alcoxi, haloalquilo, haloalcoxi, cicloalquilo o heterocicloalquilo; R⁵ es H, halo, ciano, alquilo, alcoxi, cianoalquilo, cianialcoxi, N-alquilo, dialquilamino, haloalquilo, haloalcoxi, halotioalquilo, alquilsulfinilo, alquilsulfonilo, alquilsulfona, tioalquilo, hidroxialquilo, alcoxicarbonilo, heterocicloalquilo, cicloalquilo o cicloalcoxi; o R⁴ y R⁵ están conectados para formar un cicloalquilo, un heterocicloalquilo, un heterocicloalquilo sustituido de 5 ó 6 miembros que comprende uno o dos sustituyentes seleccionados independientemente de alquilo y oxo o un anillo heteroaromático; R⁶ es H, alquilo, alquilhidroxi o haloalquilo; y sales farmacéuticamente aceptables.
ARP220100414A 2021-02-26 2022-02-25 Nuevos derivados de pirimidina-2-il sulfonamida AR124973A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP21159452 2021-02-26

Publications (1)

Publication Number Publication Date
AR124973A1 true AR124973A1 (es) 2023-05-24

Family

ID=74797733

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220100414A AR124973A1 (es) 2021-02-26 2022-02-25 Nuevos derivados de pirimidina-2-il sulfonamida

Country Status (17)

Country Link
US (1) US20240025883A1 (es)
EP (1) EP4298092A1 (es)
JP (1) JP2024507176A (es)
KR (1) KR20230152006A (es)
CN (1) CN116829550A (es)
AR (1) AR124973A1 (es)
AU (1) AU2022227183A1 (es)
CA (1) CA3203282A1 (es)
CL (1) CL2023002429A1 (es)
CO (1) CO2023010212A2 (es)
CR (1) CR20230410A (es)
IL (1) IL304450A (es)
MX (1) MX2023009045A (es)
PE (1) PE20240125A1 (es)
TW (1) TW202245749A (es)
WO (1) WO2022180136A1 (es)
ZA (1) ZA202305344B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024023129A1 (en) * 2022-07-28 2024-02-01 F. Hoffmann-La Roche Ag Novel 7-substituted indole sulfonamide derivatives
WO2024023128A1 (en) * 2022-07-28 2024-02-01 F. Hoffmann-La Roche Ag Novel 7-substituted indole sulfonamide derivatives
WO2024104462A1 (en) * 2022-11-20 2024-05-23 Myrobalan Therapeutics Nanjing Co. Ltd Gpr17 modulators and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI754702B (zh) 2016-12-28 2022-02-11 德商Ucb製藥有限公司 (氮雜)吲哚-和苯並呋喃-3-磺醯胺類
EP3584244A1 (en) * 2018-06-20 2019-12-25 UCB Pharma GmbH Substituted alkoxypyridinyl indolsulfonamides

Also Published As

Publication number Publication date
US20240025883A1 (en) 2024-01-25
WO2022180136A1 (en) 2022-09-01
IL304450A (en) 2023-09-01
KR20230152006A (ko) 2023-11-02
JP2024507176A (ja) 2024-02-16
ZA202305344B (en) 2024-01-31
MX2023009045A (es) 2023-08-10
PE20240125A1 (es) 2024-01-22
CA3203282A1 (en) 2022-09-01
TW202245749A (zh) 2022-12-01
CO2023010212A2 (es) 2023-09-08
CL2023002429A1 (es) 2024-01-12
CN116829550A (zh) 2023-09-29
CR20230410A (es) 2023-09-25
EP4298092A1 (en) 2024-01-03
AU2022227183A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
AR124973A1 (es) Nuevos derivados de pirimidina-2-il sulfonamida
AR082887A1 (es) Derivados de piridin-3-il-metil, y composiciones para la inhibicion de nampt
AR057296A1 (es) Diarilsulfona sulfonamidas y el uso de las mismas
AR082888A1 (es) Compuestos de piridina para la inhibicion de nampt
PE20030269A1 (es) Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas
AR036107A1 (es) Derivados de 6-fenilpirrolpirimidindiona, antagonista de los receptores a2 de la adenosina, particularmente del subtipo a2, de aplicacion en la prevencion de la degranulacion de los mastocitos; composiciones farmaceuticas formuladas con dichos compuestos y uso de los mismos en la preparacion de medi
AR056582A1 (es) COMPUESTOS DE PIRAZOLIL UREA CON ACTIVIDAD INHIBITORIA DE CINASA P38 Y FORMULACIoN FARMACÉUTICA QUE LO COMPRENDE
AR057989A1 (es) Derivados de indol-2-il-amida 1,5-sustituida. procesos de obtencion y composiciones farmaceuticas
AR107965A2 (es) Derivados de pirimidina
AR051387A1 (es) Analogos de anilino-pirimidina
AR045587A1 (es) Derivados de acil piperazinas sustituidas, proceso de obtencion, uso y composiciones farmaceuticas que las contienen
AR006640A1 (es) Procedimiento para la preparacion de una sal de magnesio de un sulfinil-heterociclo substituido
HUP0401784A2 (hu) Heterobiciklikus szerkezetû virális polimeráz inhibitorok, eljárás az elõállításukra, köztitermékek és ezeket tartalmazó gyógyszerkészítmények
AR053895A1 (es) Aminopirimidinas como moduladores de quinasas
PT1289955E (pt) Piperidinas para utilizacao como antagonistas dos receptores da orexina
NO20070457L (no) Pyrazolderivater
AR049543A1 (es) Derivados de la 1-amino-ftalazina, su preparacion y su aplicacion en terapeutica
AR005277A1 (es) Derivados de piperidina 1-(piperidinil 1,2 disustituido)-4-sustituidos, proceso para su preparacion, composicion farmaceutica que los contienen,proceso para preparar dichas composiciones y uso de dichos derivados como medicamentos.
AR028782A1 (es) Derivados heterociclicos tetrahidropiridino o piperidino
AR066669A1 (es) Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas.
CO6190582A2 (es) Derivados de heteroarilamida
AR070463A1 (es) Compuestos de amina y eter que modulan el receptor cb2
AR117978A1 (es) Inhibidores de 15-pgdh
AR052898A1 (es) Derivados de la n-[(4,5-difenil -2-tienil) metil] amina, su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para enfermedades mediadas por los receptores canabinoides cb1
AR056861A1 (es) Compuestos triciclicos fusionados como inhibidores de la necrosis tumoral. composiciones farmaceuticas y procesos de obtencion